Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections

PLoS Pathogens

Volumn 5, Issue 11, 2009, Pages

  Perales, Celia ^a,b   Agudo, Rubén ^a   Tejero, Hector ^a,c   Manrubia, Susanna C ^d   Domingo, Esteban ^a,b,d  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d CENTRO DE ASTROBIOLOGÍA CSIC INTA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GUANIDINE; MUTAGENIC AGENT; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIVIRAL THERAPY; ARTICLE; CELL STRAIN BHK; DRUG EFFICACY; DRUG MECHANISM; ELECTROPORATION; FOOT AND MOUTH DISEASE VIRUS; LETHAL MUTANT; MUTAGENESIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA VIRUS INFECTION; THEORETICAL MODEL; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECT; GENETICS; HAMSTER; METABOLISM; MOLECULAR EVOLUTION; MUTATION;

FOOT-AND-MOUTH DISEASE VIRUS; RNA VIRUSES;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; EVOLUTION, MOLECULAR; FOOT-AND-MOUTH DISEASE VIRUS; GUANIDINE; MODELS, BIOLOGICAL; MUTAGENS; MUTATION; RIBAVIRIN; RNA, VIRAL; VIRUS REPLICATION;

EID: 73549116556     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000658     Document Type: Article

References (111)

1. Eigen M, Schuster P (1979) The hypercycle. A principle of natural selforganization. Berlin: Springer.
2. Swetina J, Schuster P (1982) Self-replication with errors. A model for polynucleotide replication. Biophys Chem 16: 329-345.
3. Eigen M, Biebricher CK (1988) Sequence space and quasispecies distribution. In: Domingo E, Ahlquist P, Holland JJ, eds (1988) RNA Genetics. Boca Raton, FL: CRC Press. pp 211-245.
4. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, et al. (2006) Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 299: 51-82.
5. Nowak MA (2006) Evolutionary Dynamics. Cambridge, Massachusetts and London, England The Belknap Press of Harvard University Press.
6. Alves D, Fontanari JF (1998) Error threshold in finite populations. Physical Review E 57: 7008-7013.
7. Biebricher CK, Eigen M (2006) What is a quasispecies? Current Topics in Microbiol and Immunol 299: 1-31.
8. Bonhoeffer Sa, Stadler P (1993) Error thresholds on correlated fitness landscapes. J Theor Biol 164: 359-372.
9. Eigen M (2000) Natural selection: a phase transition? Biophys Chem 85: 101-123.
10. Feng X, Li Y, Gu J, Zhuo Y, Yang H (2007) Error thresholds for quasispecies on single peak Gaussian-distributed fitness landscapes. J Theor Biol 246: 28-32.
11. Nowak M, Schuster P (1989) Error thresholds of replication in finite populations mutation frequencies and the onset of Muller's ratchet. J Theor Biol 137: 375-395.
12. Schuster P, Stadler PF (2008) Early Replicons: Origin and Evolution. Origin and Evolution of Viruses 2nd edition. In: Domingo E, Parrish CR, Holland JJ, eds. Oxford: Elsevier. pp 1-42.
13. Ochoa G (2006) Error thresholds in genetic algorithms. Evol Comput 14: 157-182.
14. Takeuchi N, Hogeweg P (2007) Error-threshold exists in fitness landscapes with lethal mutants. BMC Evol Biol 7: 15; author reply 15.
15. Stich M, Briones C, Manrubia SC (2007) Collective properties of evolving molecular quasispecies. BMC Evol Biol 7: 110.
16. Eigen M (2002) Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA 99: 13374-13376.
17. Solé RV, Sardanyes J, Diez J, Mas A (2006) Information catastrophe in RNA viruses through replication thresholds. J Theor Biol 240: 353-359.
18. Bull JJ, Sanjuán R, Wilke CO (2008) Lethal mutagenesis, In: Origin and Evolution of Viruses Domingo E, Parrish C, Holland JJ, eds (2008) Elsevier. pp 207-218.
19. Batschelet E, Domingo E, Weissmann C (1976) The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene 1: 27-32.
20. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. Proc Natl Acad Sci USA 96: 13910-13913.
21. Gago S, Elena SF, Flores R, Sanjuan R (2009) Extremely high mutation rate of a hammerhead viroid. Science 323: 1308.
22. Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, et al. (2008) Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother 52: 971-979.
23. Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98: 6895-6900.
24. Anderson JP, Daifuku R, Loeb LA (2004) Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58: 183-205.
25. Domingo E, ed (2005) Virus entry into error catastrophe as a new antiviral strategy. Virus Res 107: 115-228.
26. Graci JD, Cameron CE (2002) Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298: 175-180.
27. Grande-Pérez A, Lazaro E, Lowenstein P, Domingo E, Manrubia SC (2005) Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci USA 102: 4448-4452.
28. Grande-Pérez A, Sierra S, Castro MG, Domingo E, Lowenstein PR (2002) Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci USA 99: 12938-12943.
29. Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R (2005) KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 67: 1-9.
30. Holland JJ, Domingo E, de la Torre JC, Steinhauer DA (1990) Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol 64: 3960-3962.
31. Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, et al. (1999) Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA 96: 1492-1497.
32. Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC (2003) Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308: 37-47.
33. Sierra S, Dávila M, Lowenstein PR, Domingo E (2000) Response of foot-andmouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J Virol 74: 8316-8323.
34. Graci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16: 37-48.
35. Graci JD, Harki DA, Korneeva VS, Edathil JP, Too K, et al. (2007) Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J Virol 81: 11256-11266.
36. Pariente N, Sierra S, Lowenstein PR, Domingo E (2001) Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol 75: 9723-9730.
37. Pariente N, Airaksinen A, Domingo E (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol 77: 7131-7138.
38. Pariente N, Sierra S, Airaksinen A (2005) Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res 107: 183-193.
39. Tapia N, Fernandez G, Parera M, Gomez-Mariano G, Clotet B, et al. (2005) Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 338: 1-8.
40. Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94: 6971-6976.
41. Domingo E (1989) RNA virus evolution and the control of viral disease. Prog Drug Res 33: 93-133.
42. Domingo E, Grande-Perez A, Martin V (2008) Future prospects for the treatment of rapidly evolving viral pathogens: insights from evolutionary biology. Expert Opin Biol Ther 8: 1455-1460.
43. Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333: 450-451.
44. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, et al. (2002) Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16: 21-29.
45. Nijhuis M, van Maarseveen NM, Boucher CA (2009) Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol. pp 299-320.
46. Van Vaerenbergh K, Harrer T, Schmit JC, Carbonez A, Fontaine E, et al. (2002) Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res Hum Retroviruses 18: 419-426.
47. Andrei G, De Clercq E (1993) Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res 22: 45-75.
48. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, et al. (1997) Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 24: 718-722.
49. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314: 20-26.
50. Leyssen P, De Clercq E, Neyts J (2008) Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 78: 9-25.
51. Sidwell RW, Barnard DL (2006) Respiratory syncytial virus infections: recent prospects for control. Antiviral Res 71: 379-390.
52. Shiffman ML (2008) Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. Clin Liver Dis 12: 487-505, vii.
53. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JYN, et al. (2000) The broadspectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nature Medicine 6: 1375-1379.
54. Scheidel LM, Durbin RK, Stollar V (1987) Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158: 1-7.
55. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, et al. (2003) Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38: 869-878.
56. Pfeiffer JK, Kirkegaard K (2005) Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 79: 2346-2355.
57. Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100: 7289-7294.
58. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439: 344-348.
59. Sierra M, Airaksinen A, González-López C, Agudo R, Arias A, et al. (2007) Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 81: 2012-2024.
60. Perales C, Agudo R, Domingo E (2009) Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS ONE 4: e5554. doi:10.1371/journal.-pone.0005554.
61. González-López C, Arias A, Pariente N, Gómez-Mariano G, Domingo E (2004) Preextinction viral RNA can interfere with infectivity. J Virol 78: 3319-3324.
62. Iranzo J, Manrubia SC (2009) Stochastic extinction of viral infectivity through the action of defectors. Europhysics Letters 85: 18001.
63. Perales C, Mateo R, Mateu MG, Domingo E (2007) Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol 369: 985-1000.
64. Crowder S, Kirkegaard K (2005) Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nature Genetics 37: 701-709.
65. Domingo E, Escarm?́s C, Menéndez-Arias L, Perales C, Herrera M, Novella IS, Holland JJ (2008) Viral quasispecies: dynamics, interactions and pathogenesis, In: Origin and Evolution of Viruses Domingo E, Parrish C, Holland JJ, eds. Elsevier. pp 87-118.
66. Airaksinen A, Pariente N, Menendez-Arias L, Domingo E (2003) Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311: 339-349.
67. de la Torre JC, Alarcón B, Mart?́nez-Salas E, Carrasco L, Domingo E (1987) Ribavirin cures cells of a persistent infection with foot-and-mouth disease virus in vitro. J Virol 61: 233-235.
68. Domingo E, Biebricher C, Eigen M, Holland JJ (2001) Quasispecies and RNA Virus Evolution: Principles and Consequences. Austin: Landes Bioscience.
69. Harki DA, Graci JD, Korneeva VS, Ghosh SK, Hong Z, et al. (2002) Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry 41: 9026-9033.
70. Harki DA, Graci JD, Edathil JP, Castro C, Cameron CE, et al. (2007) Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Chembiochem 8: 1359-1362.
71. Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, et al. (2006) Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J Med Chem 49: 6166-6169.
72. Gerrish PJ, Garcia-Lerma JG (2003) Mutation rate and the efficacy of antimicrobial drug treatment. The Lancet Infect Dis 3: 28-32.
73. Domingo E, Holland JJ (1992) Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet Eng (N Y) 14: 13-31.
74. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, et al. (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43: 623-629.
75. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM (2007) Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 81: 7732-7741.
76. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, et al. (2007) Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132: 1757-1766.
77. Perelson AS, Layden TJ (2007) Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 132: 2050-2052.
78. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922-924.
79. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, et al. (2002) Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 76: 8505-8517.
80. Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, et al. (2004) Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 11: 479-487.
81. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR (2003) The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310: 333-342.
82. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R (2009) The effect of ribavirin on the mutation rate and spectrum of Hepatitis C virus in vivo. J Virol.
83. Consensus Panel (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36: S3-S20.
84. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, et al. (1993) Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 37: 532-539.
85. Gilbert BE, Knight V (1986) Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 30: 201-205.
86. Ogle JW, Toltzis P, Parker WD, Alvarez N, McIntosh K, et al. (1989) Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis 159: 748-750.
87. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, et al. (2003) Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 77: 5933-5947.
88. Snell NJ (2001) Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2: 1317-1324.
89. Parker WB (2005) Metabolism and antiviral activity of ribavirin. Virus Res 107: 165-171.
90. Page T, Connor JD (1990) The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 22: 379-383.
91. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. (1986) Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578.
92. Esteban JI, Gómez J, Martell M, Guardia J (1997) Hepatitis C Virus. In: Wilson RA, ed. Viral Hepatitis. New York: Marcel Dekker. pp 147-216.
93. Alberti A (1995) Interferon therapy of acute hepatitis C. Viral Hepatol Rev 1: 37-45.
94. Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, et al. (1998) Sequential versus concomitant administration of ribavirin and interferon alfan3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 28: 341-346.
95. Asahina Y, Izumi N, Umeda N, Hosokawa T, Ueda K, et al. (2007) Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 14: 396-403.
96. Scott LJ, Perry CM (2002) Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 62: 507-556.
97. Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F (2007) Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J Gastroenterol 13: 1195-1203.
98. Giostra E, Kullak-Ublick GA, Keller W, Fried R, Vanlemmens C, et al. (2004) Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 17: 169-176.
99. Pol S, Couzigou P, Bourliere M, Abergel A, Combis JM, et al. (1999) A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J Hepatol 31: 1-7.
100. Sauleda S, Juarez A, Esteban JI, Altisent C, Ruiz I, et al. (2001) Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 34: 1035-1040.
101. McGovern BH, Abu Dayyeh BK, Chung RT (2008) Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 48: 1700-1712.
102. Thompson A, Patel K, Tillman H, McHutchison JG (2009) Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges. J Hepatol 50: 184-194.
103. Nguyen MH, Keeffe EB (2009) Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 16: 149-155.
104. Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, et al. (2009) Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther 14: 131-135.
105. Domingo E, Davila M, Ortin J (1980) Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene 11: 333-346.
106. Sobrino F, Dávila M, Ort?́n J, Domingo E (1983) Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128: 310-318.
107. Toja M (1997) Caracterización molecular de un virus de la fiebre aftosa y de sus derivados persistentes. Construcción de un clon infeccioso. Ph. D. Thesis. Madrid, Spain: Universidad Autónoma de Madrid.
108. Garc?́a-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarm?́s C (2004) Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 78: 11678-11685.
109. Arias A, Agudo R, Ferrer-Orta C, Perez-Luque R, Airaksinen A, et al. (2005) Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol 353: 1021-1032.
110. Escarm?́s C, Lazaro E, Arias A, Domingo E (2008) Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol 376: 367-379.
111. Escarm?́s C,Dávila M, Charpentier N, Bracho A, Moya A, et al. (1996) Genetic lesions associated with Muller's ratchet in an RNA virus. J Mol Biol 264: 255-267.